Showing results (1581-1590 of 1,751) with videos related to

Sort By:
Pageof 176
Aging Clinical and Experimental Research|February 2, 2020
Driving status and health-related quality of life among the oldest old: a population-based examination using data from the AgeCoDe-AgeQualiDe prospective cohort studyAndré Hajek, Christian Brettschneider, Dagmar Lühmann, et al.
Leukemia & Lymphoma|September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general populationHeinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.
Leukemia & Lymphoma|July 24, 2018
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 casesArtur Jurczyszyn, Julio Davila, K Martin Kortüm, et al.
Plos One|April 16, 2015
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyJiri Minarik, Petr Pavlicek, Ludek Pour, et al.
American Journal of Human Genetics|July 11, 2006
Mutation in TRMU related to transfer RNA modification modulates the phenotypic expression of the deafness-associated mitochondrial 12S ribosomal RNA mutationsMin-Xin Guan, Qingfeng Yan, Xiaoming Li, et al.
International Journal of Geriatric Psychiatry|March 27, 2021
Correlates of institutionalization among the oldest old-Evidence from the multicenter AgeCoDe-AgeQualiDe studyAndré Hajek, Melanie Luppa, Christian Brettschneider, et al.
British Journal of Haematology|April 7, 2017
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II studyOrhan Sezer, Meral Beksac, Roman Hajek, et al.
Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.
Haematologica|June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugsVittorio Montefusco, Francesca Gay, Stefano Spada, et al.
Blood|February 5, 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Nikhil C Munshi, Kenneth C Anderson, P Leif Bergsagel, et al.
Pageof 176